{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:18:38Z","timestamp":1736486318198,"version":"3.32.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic cancer is a highly aggressive malignancy with the majority of patients presenting at a late stage with unresectable or metastatic disease. Even with first line treatment, median survival is approximately 11 months in patients with advanced PDAC. This report details the unique case of a patient that presented with peritoneal metastases from an adenocarcinoma of the body of the pancreas, had a remarkable response to palliative chemotherapy and is alive without evidence of disease 12 months following cessation of all active treatment. The initial diagnosis was 4 years ago and extensive resection of the primary was completed 2 years ago. The patient was started on standard FOLFIRINOX chemotherapy regimen, completed 6 cycles, but stopped Oxaliplatin and Irinotecan due to neuropathy and fatigue, on November 5, 2020, and transitioned to 5-fluorouracil (5-FU) and leucovorin. There was radiographic response and a notable decrease in tumor marker CA 19-9. On July 12, 2022 he underwent a multivisceral resection that included a radical anterograde modular pancreatico-splenectomy, partial gastrectomy, and splenic flexure colectomy with primary anastomosis due to tumor involvement of the posterior stomach and splenic flexure. Surgical pathology noted a moderately differentiated, grade 2 tumor staged ypT2 N0 M0. He continued the same adjuvant regimen of 5-FU and leucovorin for approximately 9 months with no new or recurrent disease on imaging. His CA 19-9 decreased within normal range after surgery and has remained within the normal limits. He remains on active surveillance. Overall, barring clear availability for targeted therapies, a metastatic PDAC of the tail may be considered to have a better prognosis than previously considered. FOLFIRINOX is the ideal treatment if the patient has a high-performance status, and PRODIGE 35 recommends 8 minimum cycles. However, in our case, the patient only tolerated 6 cycles and was still highly responsive. Despite a stage IV diagnosis, the primary tumor was resected in order to mitigate the risk for mutation and progression. Although rare, greater hope for patients with PDAC of the tail with favorable tumor biology responsive to FOLFIRINOX may contribute to increased surgical resection rates and improve survival rates.<\/jats:p>","DOI":"10.1007\/s12672-025-01756-4","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:14:19Z","timestamp":1736421259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic pancreatic cancer now in remission: a case report and literature review"],"prefix":"10.1007","volume":"16","author":[{"given":"Charles W.","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"VanderMeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Pudusseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"1756_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2129884","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023. https:\/\/doi.org\/10.1080\/08941939.2022.2129884.","journal-title":"J Invest Surg"},{"issue":"11","key":"1756_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/jca.14922","volume":"7","author":"K Polireddy","year":"2016","unstructured":"Polireddy K, Chen Q. Cancer of the pancreas: molecular pathways and current advancement in treatment. J Cancer. 2016;7(11):1497\u2013514. https:\/\/doi.org\/10.7150\/jca.14922.","journal-title":"J Cancer"},{"issue":"1","key":"1756_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1756_CR4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Can Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155.","journal-title":"Can Res"},{"issue":"48","key":"1756_CR5","doi-asserted-by":"publisher","first-page":"6827","DOI":"10.3748\/wjg.v28.i48.6827","volume":"28","author":"CY Zhang","year":"2022","unstructured":"Zhang CY, Liu S, Yang M. Clinical diagnosis and management of pancreatic cancer: markers, molecular mechanisms, and treatment options. World J Gastroenterol. 2022;28(48):6827\u201345. https:\/\/doi.org\/10.3748\/wjg.v28.i48.6827.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1756_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014.","journal-title":"Cell"},{"issue":"20","key":"1756_CR7","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.3748\/wjg.v21.i20.6384","volume":"21","author":"S Schneitler","year":"2015","unstructured":"Schneitler S, Kr\u00f6pil P, Riemer J, et al. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol. 2015;21(20):6384\u201390. https:\/\/doi.org\/10.3748\/wjg.v21.i20.6384.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1756_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00330-020-07188-8","volume":"31","author":"JK Jang","year":"2021","unstructured":"Jang JK, Byun JH, Kang JH, et al. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Eur Radiol. 2021;31(2):813\u201323. https:\/\/doi.org\/10.1007\/s00330-020-07188-8.","journal-title":"Eur Radiol"},{"key":"1756_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000367966","author":"V Kunzmann","year":"2014","unstructured":"Kunzmann V, Herrmann K, Hartlapp I, Steger U, Bluemel C, Kapp M. Intensified neoadjuvant chemotherapy with Nab -Paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced Unresectable pancreatic cancer. Case Reports Oncol. 2014. https:\/\/doi.org\/10.1159\/000367966.","journal-title":"Case Reports Oncol"},{"issue":"25","key":"1756_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000020564","volume":"99","author":"H Sato","year":"2020","unstructured":"Sato H, Sasajima J, Okada T, et al. Resection for pancreatic cancer metastases contributes to survival. Medicine. 2020;99(25): e20564. https:\/\/doi.org\/10.1097\/md.0000000000020564.","journal-title":"Medicine"},{"issue":"6","key":"1756_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000497827","volume":"35","author":"AM Luu","year":"2019","unstructured":"Luu AM, Hoehn P, Vogel SR, et al. Pathologic complete response of pancreatic cancer following neoadjuvant FOLFIRINOX treatment in hepatic metastasized pancreatic cancer. Visceral Med. 2019;35(6):387\u201390. https:\/\/doi.org\/10.1159\/000497827.","journal-title":"Visceral Med"},{"issue":"2","key":"1756_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/jgo.2018.01.07","volume":"9","author":"AM Luu","year":"2018","unstructured":"Luu AM, Herzog T, Hoehn P, et al. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol. 2018;9(2):9\u201312. https:\/\/doi.org\/10.21037\/jgo.2018.01.07.","journal-title":"J Gastrointest Oncol"},{"key":"1756_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/AJCR.923803","volume":"21","author":"NR Patil","year":"2020","unstructured":"Patil NR, Khan GN. Exceptional response to a single cycle of immunotherapy in a lynch syndrome patient with metastatic pancreatic adenocarcinoma. Am J Case Reports. 2020;21:1\u20136. https:\/\/doi.org\/10.12659\/AJCR.923803.","journal-title":"Am J Case Reports"},{"issue":"2","key":"1756_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.7759\/cureus.13133","volume":"13","author":"S Atiq","year":"2021","unstructured":"Atiq S, Atiq OO, Atiq ZO, Samad S, Atiq O. A case of metastatic pancreatic adenocarcinoma in complete remission using chemotherapy and immunotherapy. Cureus. 2021;13(2):2\u20135. https:\/\/doi.org\/10.7759\/cureus.13133.","journal-title":"Cureus"},{"key":"1756_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a005553","author":"E Busch","year":"2020","unstructured":"Busch E, Kreutzfeldt S, Agaimy A, et al. Successful BRAF \/ MEK inhibition in a patient with BRAF V600E -mutated extrapancreatic acinar cell carcinoma. Mol Case Stud. 2020. https:\/\/doi.org\/10.1101\/mcs.a005553.","journal-title":"Mol Case Stud"},{"issue":"2","key":"1756_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12328-022-01741-2","volume":"16","author":"K Okada","year":"2023","unstructured":"Okada K, Uemura K, Okamoto W, et al. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. Clin J Gastroenterol. 2023;16(2):283\u20138. https:\/\/doi.org\/10.1007\/s12328-022-01741-2.","journal-title":"Clin J Gastroenterol"},{"issue":"18","key":"1756_CR17","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1089\/ars.2012.5107","volume":"18","author":"J Li","year":"2013","unstructured":"Li J, Braganza A, Sobol RW. Base excision repair facilitates a functional relationship between guanine oxidation and histone demethylation. Antioxid Redox Signal. 2013;18(18):2429\u201343. https:\/\/doi.org\/10.1089\/ars.2012.5107.","journal-title":"Antioxid Redox Signal"},{"key":"1756_CR18","unstructured":"Kuiper RP, Nielsen M, De Voer RM, Hoogerbrugge N. NTHL1 Tumor Syndrome. 1993."},{"key":"1756_CR19","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2020.03.02","author":"J Gu","year":"2020","unstructured":"Gu J, Xu Z, Ma Y, Chen H, Wang D, Deng XCD. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. J Gastroint Oncol. 2020. https:\/\/doi.org\/10.21037\/jgo.2020.03.02.","journal-title":"J Gastroint Oncol"},{"issue":"2","key":"1756_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000509231","volume":"37","author":"P H\u00f6hn","year":"2021","unstructured":"H\u00f6hn P, Braumann C, N\u00f6pel-D\u00fcnnebacke S, Munding J, Uhl W, Luu AM. Recurrence of pancreatic ductal adenocarcinoma after complete histopathological remission caused by FOLFIRINOX. Visceral Med. 2021;37(2):149\u201353. https:\/\/doi.org\/10.1159\/000509231.","journal-title":"Visceral Med"},{"issue":"4","key":"1756_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Zum BCM, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):1\u201315. https:\/\/doi.org\/10.1371\/journal.pmed.1000267.","journal-title":"PLoS Med"},{"issue":"9","key":"1756_CR22","first-page":"4125","volume":"32","author":"V Lorgis","year":"2012","unstructured":"Lorgis V, Chauffert B, Gentil J, Ghiringhelli F. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil\/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res. 2012;32(9):4125\u201330.","journal-title":"Anticancer Res"},{"issue":"19","key":"1756_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/nejmoa1011923.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01756-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:17:17Z","timestamp":1736425037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01756-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient to participate in the study and for publication. The U.S. Department of Health and Human Services defines Research as a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. This case report does not meet the Rule\u2019s definition for research and did not require institutional review board approval for publication. Health information has been de-identified in accordance with 45 CFR 165.502(d), and 164.514(a)-(c) of the HIPAA Privacy Rule.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient to participate in the study and for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}